These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 10741701

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
    Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M.
    Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
    [Abstract] [Full Text] [Related]

  • 4. Clinical pharmacokinetics of irinotecan.
    Chabot GG.
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [Abstract] [Full Text] [Related]

  • 5. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
    Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML.
    J Clin Oncol; 1999 Feb; 17(2):685-96. PubMed ID: 10080615
    [Abstract] [Full Text] [Related]

  • 6. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
    Stewart CF, Panetta JC, O'Shaughnessy MA, Throm SL, Fraga CH, Owens T, Liu T, Billups C, Rodriguez-Galindo C, Gajjar A, Furman WL, McGregor LM.
    J Clin Oncol; 2007 Jun 20; 25(18):2594-600. PubMed ID: 17577039
    [Abstract] [Full Text] [Related]

  • 7. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
    Gajjar A, Chintagumpala MM, Bowers DC, Jones-Wallace D, Stewart CF, Crews KR.
    Cancer; 2003 May 01; 97(9 Suppl):2374-80. PubMed ID: 12712459
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase I study of irinotecan in pediatric patients with malignant solid tumors.
    Mugishima H, Matsunaga T, Yagi K, Asami K, Mimaya J, Suita S, Kishimoto T, Sawada T, Tsuchida Y, Kaneko M.
    J Pediatr Hematol Oncol; 2002 Feb 01; 24(2):94-100. PubMed ID: 11990713
    [Abstract] [Full Text] [Related]

  • 12. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
    Crews KR, Stewart CF, Jones-Wallace D, Thompson SJ, Houghton PJ, Heideman RL, Fouladi M, Bowers DC, Chintagumpala MM, Gajjar A.
    Clin Cancer Res; 2002 Jul 01; 8(7):2202-9. PubMed ID: 12114421
    [Abstract] [Full Text] [Related]

  • 13. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice.
    Stewart CF, Zamboni WC, Crom WR, Houghton PJ.
    Cancer Chemother Pharmacol; 1997 Jul 01; 40(3):259-65. PubMed ID: 9219511
    [Abstract] [Full Text] [Related]

  • 14. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Hérait P, Armand JP, Bugat R.
    Ann Oncol; 1995 Feb 01; 6(2):141-51. PubMed ID: 7786822
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
    Thompson PA, Gupta M, Rosner GL, Yu A, Barrett J, Bomgaars L, Bernstein ML, Blaney SM, Mondick J.
    Cancer Chemother Pharmacol; 2008 Nov 01; 62(6):1027-37. PubMed ID: 18278496
    [Abstract] [Full Text] [Related]

  • 16. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
    de Forni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A, Madelaine I, Marty ME, Mathieu-Boué A.
    Cancer Res; 1994 Aug 15; 54(16):4347-54. PubMed ID: 8044782
    [Abstract] [Full Text] [Related]

  • 17. Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks.
    Minami H, Fujii H, Igarashi T, Itoh K, Tamanoi K, Oguma T, Sasaki Y.
    Clin Cancer Res; 2001 Oct 15; 7(10):3056-64. PubMed ID: 11595695
    [Abstract] [Full Text] [Related]

  • 18. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
    Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL.
    Clin Cancer Res; 2000 Jun 15; 6(6):2236-44. PubMed ID: 10873073
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
    Herben VM, Schellens JH, Swart M, Gruia G, Vernillet L, Beijnen JH, ten Bokkel Huinink WW.
    J Clin Oncol; 1999 Jun 15; 17(6):1897-905. PubMed ID: 10561231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.